We are organising the In Silico Drug Safety and Efficacy Symposium in Oxford on Sept 21-22, 2017, in the context of the NC3R Infrastructure of Impact Award and the Quantitative Systems Pharmacology Network.
We will have presentations and discussions on all aspects of cardiotoxicity across industry, academia, hospitals and regulatory agencies. Registration will be free but confirmation of attendance is needed. If you are interested, please contact us as soon as possible.
There will be a whole day of diverse presentations and discussions followed by dinner on Sept 21st, and more activities in the morning of Sept 22nd finishing with lunch. This will enable travelling to the Safety Pharmacology Society meeting in Berlin or Computing in Cardiology in Rennes.
The workshop, co-organised by the NC3Rs, SPS and Coventry University, aims to bring together researchers from academia, SMEs and the pharmaceutical industry to discuss how best to support and enable the use of human tissues in safety testing. The one-day workshop will be held in Coventry, UK on Wednesday 03 May 2017.
The workshop is part of a wider NC3Rs initiative to improve the predictive capacity and relevance of research models to human safety testing, and to implement human tissue as a replacement for animal models.
The programme consists of presentations, posters, exhibitors and networking opportunities. Researchers from academia and industry will speak in three sessions:
Elisa Passini is presenting a poster on: "Human-based in Silico Drug Trials Predict Drug Cardiotoxicity and Identify Sub-Populations at Higher Risk" and Cristian Trovato is presenting a poster entitled: “In Silico Population of human models to investigate drug cardiotoxicity in cardiac Purkinje cells”.
The Medical Sciences Division and Department of Biomedical Services Oxford 3Rs Research Day will be held on Friday the 24th of February 10:00-17:00. It will cover advances in reduction, refinement and replacement of animals and will feature both local and national speakers, including the National Centre for the Replacement, Refinenment and Reduction of Animals in Research. The event is suppported by "Understanding Animal Research" and the NC3Rs.
We will take this oppportunity to discuss the advantages of "in silico" methodologies and Elisa Passini will give a talk on "In Silico Drug Trials Predict Drugs Cardiotoxicity and Identify Sub-Populations at Higher Risk"
Funded by the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking, this five-year project “Translational Quantitative Systems Toxicology (TransQST)” aims at developing novel computational approaches using the best available data from the public and private domains to address drug safety challenges. The main organs that will be object of research during this project will be the cardiovascular, the liver, the kidney and the gastrointestinal systems.
TransQST is a partnership between ten academic institutions, including some of the participants on the "In Silico Human drug safety and efficacy" project. The project will be coordinated by the University of Liverpool, and the pharmaceutical company AbbVie is the Project Leader.
This year The Gordon Research Conference on Cardiac Arrhythmia Mechanisms will take place in California, February 5th-10th.
This conference brings a great opportunity to spend some days with key players on the fiedl. The conference addresses the need of basic science discovery, the power of model systems and the new technologies that ultimately enable patient-specific mechanistic approaches to disease diagnosis and treatment. The long-term objective of this meeting is to provide a forum for investigators – junior, mid-level and senior – to engage in focused discussion on the latest advances in the field of cardiac arrhythmia mechanisms. The meeting fosters the development of trainees by supporting an associated Gordon Research Seminar (GRS) on Cardiac Arrhythmia Mechanisms at which trainees present their research findings and engage in panel discussions with mentors on matters of career pathways and professional development.
The 2017 meeting will highlight a range of disciplines including new mechanisms of arrhythmia, the role of population variation in computational model development and transcriptional and translational mechanisms regulating cardiac excitability. Approximately 50 speakers have been selected to present cutting-edge work that is largely unpublished. Poster sessions will provide additional opportunity for collegial interactions over refreshments.
We will take this opportunity to present the project “In Silico Human drug safety and efficacy” and show the advantages of using in silico models to test drug safety and efficacy. Elisa Passini will present the latest research on "Human-based in Silico Drug Trials Predict Drug Cardiotoxicity and Identify Sub-Populations at Higher Risk" and Blanca Rodriguez will give a presentation on "Experimentally Calibrated Population of Models Predicts and Explains Inter-Subject Variability".
Frontiers is preparing a special issue on "Safety Pharmacology, Risk Assessment QT Interval Prolongation and Beyond at Frontiers". The deadline for expression of interest it the 1st of March and for manuscripts the 1st of July. Please visit here for more information.
The editors for this special topic are; Eleonora Grandi and Stefano Morotti, (The University of California, Davis, USA) Esther Pueyo, (University of Zaragoza, Spain) and Blanca Rodriguez (University of Oxford, UK).
The Comprehensive In Vitro Proarrhythmia Assay (CIPA) Update Meeting will be held in the Washington, DC area, on Tuesday December 6th, 2016, in collaboration with the Health and Environmental Sciences Institute (HESI).
The CIPA seeks to markedly transform the assessment of drugs for their proarrhythmic potential, replacing the current focus on ECG QT assessment. This multi-national effort is moving towards completion in 2017. This important meeting will bring together stakeholders from industry, academia, multiple regulatory agencies, and CRO’s to discuss the current scientific status of CiPA, how it will impact drug development, and the evolving regulatory framework. This should be a highly interactive and impactful meeting.
The Health and Environmental Sciences Institute (HESI) is a non-profit institution whose mission is to collaboratively identify and help to resolve global health and environment challenges through the engagement of scientists from academia, government, industry, NGOs, and other strategic partners.
Alfonso Bueno-Orovio will be a panelist and will be actively participating on this meeting and taking this opportunity to discuss the advantages of in silico assays on cardiovascular research.
For registration click HERE
The Safety Phamacology Society meeting was held in Vancouver between the 18th and the 21st of September. As part of the meeting, a special session was organised on "Advances in Technologies—In Vitro and In Silico Models". This session provided insight into the latest knowledge and development in the fields of cardiac safety science and bioimaging. The aim was to show that these scientific innovations and developments could be of benefit for reducing attrition in drug development.
Two presentations were given during this session on In silico models:
"Towards In Silico Drug Trials in Safety Pharmacology" by Blanca Rodriguez, The University of Oxford, UK and "An In Silico ECG Database of Drug Effects for Proarrhythmic Risk Assessment by Heart Simulator Jun-ichi Okada" The University of Tokyo, Japan.
Posters on the topic were also presented:
"Investigation of inter-individual variability in electrophysiological response to drug block using human ex-vivo ventricular preparations and heart-specific populations of cardiomyocyte models." (Blanca Rodriguez et al), "A Novel In Silico Human Cardiac Purkinje Cell Model to Investigate Drug Safety and Efficacy" (E. Passini, et al), "In Silico Drug Trials with Virtual Assay Software Predict Drug Cardiotoxicity and Identify Sub-Populations at Higher Risk" (E. Passini, et al), "Comparative Evaluation of In Silico Models to Assess Cardiac Pro-Arrhythmic Risk in Early Drug Development" (P. Morissette, et al), Simulation of IQ-CSRC Prospective Study Using Integrated In Silico 2-Dimensional Transmural Human Ventricular Wedge Preparation Model" (T. Kubo, et al).
This was a great opportunity to show the advantages of using in silico methods on drug safety and efficacy.
The NC3Rs and the international Health and Environmental Sciences Institute, HESI, hosted a two day workshop to understand the challenges and opportunities in accelerating acceptance of evidence provided from mathematical models to improve the predictivity of efficacy and safety testing for drugs and chemicals. The workshop was held in central London on 14 and 15 September 2016.
Alfonso Bueno gave a talk at the workshop on the 14th of September at the session "Does model complexity influence confidence", moderated by Syril Petit (HESI), and his talk was on "Mathematical predictions of cardiac toxicity in human: Advances towards the 3Rs in Safety Pharmacology".
This project "In Silico human-based methodologies for evaluation of drug safety and efficacy" has received funding from The National Centre for the Replacement, Refinement and Reduction of Animals in Research
Driven by 
Newt
Home | Site Map | Contact | Freedom of Information | Privacy Policy | Copyright | Accessibility | Oxford University
